M

Merck

Makes medicines, vaccines and animal treatments

Executive Director - Head, Global Trial Optimization

Full-TimePosted on 10/23/2026Deadline 11/6/26
$255.8k - $402.7k+ Annual bonus + Long-term incentive
Expert
Bachelor's
Upper Gwynedd Township, PA, USA+1 moreMore locations: Rahway, NJ, USA
HybridHybrid work arrangement; travel required 25%.
Biology & BiotechClinical Research Operations
H1B Sponsorship Available

About the job

Requirements
  • A minimum of 15 years of clinical research experience in the pharmaceutical industry in the United States and ex-United States.
  • Demonstrate understanding of and commitment to the company's Leadership principles, emphasizing collaboration, rapid and disciplined decision-making, and integrity and ethics.
  • Have proficiency in written and spoken English and communicate effectively in writing and verbally, including influencing and representing the organization at senior regional and global levels.
  • Sponsor enterprise-level digital, analytics, automation-enabled, and approved artificial-intelligence-enabled capabilities, and use data-driven insights to shape portfolio, organizational, and resource strategy.
  • Establish and govern risk-informed decision frameworks across the portfolio, balancing quality, compliance, business objectives, resources, and strategic priorities.
  • Apply enterprise-level judgment to complex and ambiguous situations, anticipate future organizational needs, and guide strategic decisions affecting long-term clinical operations performance.
  • Build a culture of agility, innovation, and continuous improvement to respond proactively to evolving business, regulatory, technology, and portfolio demands.
  • Own governance frameworks, escalation pathways, and outcomes within delegated authority and enterprise expectations.
  • Create and champion organizational opportunities using knowledge of the pipeline, patient and investigator landscape, health systems, and external environment; align pipeline, platforms, policy, and people; embed end-to-end ownership; and direct innovation and operating-model choices that strengthen competitiveness and patient access to trials.
  • Set strategy and execution direction by defining portfolio and capability priorities, investment and resource choices, scenarios, required conditions, trade-offs, and governance; translate direction into execution standards and measurable outcomes; and reallocate resources to protect pipeline delivery, quality, and long-term organizational capability.
  • Influence senior internal and external stakeholders and champion the global trial optimization network across the company's research division, GCD, GCTO, countries, institutions, investigators, and vendors; build partnerships, represent the organization in strategic discussions and governance forums, and shape accountabilities that reduce silos and advance capability, pipeline delivery, and clinical research outcomes.
  • Have project management or Site Ready support knowledge and experience.
  • Know and be able to apply Good Clinical Practice, International Council for Harmonisation, and applicable regulatory guidelines.
  • Have superior presentation skills.
  • Have training and curriculum development experience.
  • Have computer skills, including proficiency in data analysis and presentation software, Microsoft Word, and Microsoft Excel.
  • Have proficiency in Clinical Research Organization management, clinical trials operations, cross-cultural awareness, influence, people leadership, resource allocation, results orientation, and strategic thinking.
Responsibilities
  • Ensure assigned deliverables meet regulatory, business, and patient-centricity standards, as appropriate, and that functional contributions support strategic approaches rather than transactional tasks; implement forward-thinking approaches to improve quality and ease of compliance; serve as the subject matter expert for Global Trial Optimization.
  • Provide vision, leadership, and oversight to the Global Trial Optimization group in implementing data-driven approaches to feasibility and developing recruitment and retention strategies; communicate progress, status updates, mitigation plans, and escalations for trial- or program-level deliverables to senior management.
  • Provide strategic leadership, coaching, and people management for the Global Trial Optimization leadership team; ensure high-quality deliverables and issue resolution across the portfolio, including Program Review, program and trial feasibility, allocation, and recruitment strategies, plans, and tactics.
  • Ensure staff are trained to use Real World Data in trial execution simulations based on protocol and patient knowledge and collaborations with PDT members.
  • Identify portfolio-level risks and ensure appropriate mitigation strategies are developed and implemented across programs.
  • Support trial execution by implementing streamlined enterprise-level vendors where needed and standardizing the digital presence while retaining flexibility to customize tactics.
  • Drive compliance with the GCTO Country footprint strategy and respond to internal and external challenges by evolving and adapting processes as the business landscape changes.
  • Provide strategic and operational oversight of the Trial Engagement and Site Partnership organization, ensuring integrated, fit-for-purpose strategies that strengthen investigator and site relationships, improve the site experience, and support trial screening, enrollment, retention, and execution.
  • Partner with GCTO team members to develop strategies and processes that enable key GCTO innovations in end-to-end clinical trial execution.
  • Work closely with CSSM, CQM, Country Operations, GPAM, Clinical Directors, Legal, and other stakeholders to anticipate upcoming study needs and address them promptly.
  • Determine resource needs by reviewing authorized and anticipated clinical development activities and collaborating closely with CSSM and GPAM leaders.
  • Keep abreast of pharmaceutical industry best practices, regulatory requirements, and corporate strategies that affect the organization.
  • Drive continuous improvement within Global Trial Optimization to optimize predictability and accuracy of deliverables.
  • Collaborate to establish performance metrics and monitor them to enhance capabilities and improve overall quality.
  • May lead operational components of mergers and acquisitions, including due diligence activities and portfolio integrations.
  • May lead and/or implement process improvement and strategic initiatives.
Desired Qualifications
  • Proficiency with data modelling software, where applicable.
  • Process management experience.
  • International collaboration experience.
  • Sigma training.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Citybiz
Oct 20th, 2026
Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors.

Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors. October 20, 2026 Enoch Kariuki Epicrispr Biotechnologies, a clinical-stage biotechnology company developing epigenetic therapies, has appointed Enoch Kariuki, PharmD, to its Board of Directors as the company advances its lead treatment candidate, EPI-321, toward pivotal clinical development and expands its pipeline of gene-modulating medicines. Kariuki brings extensive experience in biotechnology operations, corporate strategy, capital markets and business development. Throughout his career, he has participated in more than $10 billion in strategic financings and mergers and acquisitions across the life sciences industry. His appointment strengthens Epicrispr's board as the company works to advance its clinical programs, evaluate development priorities and establish the financial and operational infrastructure needed to support future growth. "Enoch is an accomplished biotechnology leader with a proven track record of building and scaling companies, guiding programs through pivotal clinical and regulatory milestones, and executing strategic transactions that create lasting value," said Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies. Salzman said Kariuki's combination of operational, financial and strategic experience will support the company's efforts to advance EPI-321 and develop additional epigenetic medicines. Kariuki currently serves as President of Endeavor BioMedicines, where he oversees corporate strategy and operations. His responsibilities include guiding organizational development and supporting the company's business and clinical development objectives. Previously, he served as CEO of Lengo Therapeutics, a biotechnology company acquired by Blueprint Medicines. He also held the position of Chief Financial Officer at VelosBio, which was acquired by Merck. Earlier in his career, Kariuki was Senior Vice President of Corporate Development at Synthorx, where he led the company's initial public offering and played a significant role in its subsequent acquisition by Sanofi. His experience also includes investment and advisory positions at H.I.G. Capital, Leerink Partners and UBS Investment Bank, providing a background in financing, strategic transactions and biotechnology investment analysis. These roles have given Kariuki experience across multiple stages of biotechnology company development, from securing financing and establishing corporate strategy to executing acquisitions and supporting clinical-stage growth. At Epicrispr, that experience will be relevant as the company evaluates the resources, partnerships and development strategies required to advance its therapeutic programs. Epicrispr's lead candidate, EPI-321, is being evaluated in clinical trials for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease characterized by progressive muscle weakness. The company is developing EPI-321 using its proprietary Gene Expression Modulation System (GEMS), an epigenetic technology platform designed to regulate gene expression without directly changing the underlying DNA sequence. Epigenetic therapies seek to influence how genes are activated or suppressed. Epicrispr's approach is intended to provide precise and durable modulation of gene activity, potentially addressing diseases associated with abnormal gene expression. The company is initially concentrating on neuromuscular disorders while developing additional gene-modulating treatments for other conditions. Advancing EPI-321 toward pivotal development represents an important operational priority. Clinical-stage biotechnology companies approaching later-stage trials must address study design, regulatory engagement, manufacturing readiness, financing requirements and long-term commercialization planning. Board members with experience in clinical development and capital markets can provide oversight as management evaluates those requirements and determines how to allocate resources across its pipeline. "Epicrispr is at an exciting inflection point, with compelling early clinical data supporting the potential of its differentiated epigenetic platform to address diseases with significant unmet medical needs," Kariuki said. He identified EPI-321's development in FSHD and the company's broader epigenetic technology platform as areas of opportunity, while emphasizing his intention to support Epicrispr's strategic priorities. In addition to his executive responsibilities, Kariuki serves on the boards of Zentalis Pharmaceuticals and Pheon Therapeutics, chairing the audit committees at both companies. He previously served on the boards of Imago Biosciences and ProfoundBio, which were acquired by Merck and Genmab, respectively. His board experience includes financial oversight and corporate governance responsibilities relevant to biotechnology companies operating in capital-intensive research and development environments. Kariuki earned a Doctor of Pharmacy degree from Texas Southern University and an MBA from the Tuck School of Business at Dartmouth College. He also completed a postdoctoral fellowship in research and development strategy and analytics at Bristol Myers Squibb. Epicrispr continues to advance EPI-321 through clinical development while expanding its portfolio of gene-modulating therapies. Kariuki's appointment adds biotechnology financing, transaction and operational experience to the board as the company prepares for its next stage of clinical development and evaluates opportunities to advance its epigenetic medicines platform.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.